Cardiology Development Doctors Trials 
Velocity Clinical Research
DECEMBER 6, 2023
In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Velocity Clinical Research Velocity is the leading integrated site organization for clinical trials. and Europe.
Velocity Clinical Research
JANUARY 3, 2024
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. In most cases, the participant of a clinical trial benefits from taking part, which is of great importance, especially in oncological trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 16, 2020
People always say that patients and doctors should share decision making and discuss treatments with one another, but in reality, most of us just follow the guidelines. The only problem at the moment is that it’s not what doctors are taught to do. He adds that the most important aspect of this approach is its simplicity and logic. “I’ve
The Pharma Data
NOVEMBER 4, 2020
If your doctor decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible. Your doctor will decide if you need additional vaccination. Your doctor will give you a Patient Safety Card about the risk of meningococcal infection.
The Pharma Data
JULY 8, 2021
When added to the EMPEROR-Reduced trial results, these findings demonstrate Jardiance’s efficacy in all forms of heart failure regardless of ejection fraction. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.
The Pharma Data
NOVEMBER 4, 2020
Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Research and development (R&D) expense for the three and nine months ended September 30, 2020 were $10.2
The Pharma Data
NOVEMBER 16, 2020
The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. For the trial, more than 5,700 people from nine countries were randomly assigned to one of four groups.
Expert insights. Personalized for you.
52 
Let's personalize your content